Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06673667 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
A Phase 1 study, sponsored by Kymera Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
NCT06673667 is a Phase 1 study that has completed, run by Kymera Therapeutics. The registered enrollment target is 118 participants.
The verdict
NCT06673667, a Phase 1 study, has completed, sponsored by Kymera Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
Study Summary
This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.
Interventions
- DRUG Placebo
- DRUG KT-621
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2025-04-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06673667
The ClinicalTrials.gov registry entry for NCT06673667 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kymera Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06673667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06673667 about?
NCT06673667 is a clinical study titled "First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants". This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.
What is the current status of trial NCT06673667?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2024-10-22. Estimated completion is 2025-04-23.
What interventions are being tested in trial NCT06673667?
The interventions under investigation include: Placebo (DRUG), KT-621 (DRUG).
Who is sponsoring clinical trial NCT06673667?
This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.